BioPharmSignal logoBioPharmSignal

Biotech News

GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation

GSK plc (GSK)GSK plcCompany update

Real-world data shows an association between Recombinant Zoster Vaccine (RZV) and potential reduced risk of dementia.

Related news

GSKGSK plc2026-10-26 15:30 EST

Ris-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China

GSKGSK plc2026-11-05 15:08 EST

GSK showcases progress in liver portfolio at AASLD 2026

LEGNLegend Biotech Corporation2026-11-04 14:00 EST

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

BMYBMYBristol-Myers Squibb Company2026-10-19 10:59 EST

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

BMYBMYBristol-Myers Squibb Company2026-10-23 11:30 EST

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

View all latest news

GSK plc

Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...

Recent company news

GSKGSK plc2026-11-05 15:08 EST

GSK showcases progress in liver portfolio at AASLD 2026

GSKGSK plc2026-10-28 07:00 EST

GSK delivers strong Q3 performance and continued momentum

GSKGSK plc2026-10-26 15:30 EST

Ris-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China

GSKGSK plc2026-10-24 23:00 EST

Jemperli (dostarlimab) data show 76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

Stock data

Close
50.41 USD
Market cap
98.26B USD
Exchange
NYSE
Sector
Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
Location
United States